1-benzyl-2-thio-5,6-dihydrouracil profile

1-Benzyl-2-thio-5,6-dihydrouracil is a synthetic compound that belongs to the class of **thiazolidine-2,4-diones**, also known as **TZDs**.

**Here's what makes it interesting for research:**

* **Analogous to natural compounds:** It shares structural similarities with natural compounds like thiazolidinedione (TZD) derivatives, which have been shown to exhibit a variety of biological activities.
* **Potential for biological activity:** TZDs, like 1-benzyl-2-thio-5,6-dihydrouracil, are being studied for their potential in various therapeutic applications, including:
* **Antidiabetic activity:** Some TZDs have been found to improve insulin sensitivity and glucose utilization, which makes them promising agents for the treatment of type 2 diabetes.
* **Anti-inflammatory activity:** TZDs have shown anti-inflammatory properties and are being investigated for their potential in treating inflammatory diseases.
* **Anti-cancer activity:** Certain TZDs are being explored for their ability to inhibit the growth and spread of cancer cells.
* **Versatile scaffold:** The structure of 1-benzyl-2-thio-5,6-dihydrouracil can be readily modified by introducing different substituents at various positions, making it a versatile scaffold for synthesizing a wide array of TZDs with varying biological activities.

**Important research areas:**

* **Drug discovery:** Researchers are actively exploring the synthesis and biological evaluation of 1-benzyl-2-thio-5,6-dihydrouracil and its derivatives to discover novel therapeutic agents for various diseases.
* **Structure-activity relationship (SAR):** Studying how modifications to the structure of 1-benzyl-2-thio-5,6-dihydrouracil affect its biological activity is crucial for optimizing the design of new TZDs.
* **Mechanism of action:** Understanding the molecular mechanisms by which 1-benzyl-2-thio-5,6-dihydrouracil and its derivatives exert their biological effects is essential for developing targeted therapies.

**Note:** While 1-benzyl-2-thio-5,6-dihydrouracil shows potential, it's important to emphasize that the compound is still under research and its safety and efficacy haven't been fully established. Further studies are needed before it can be considered for clinical use.

1-benzyl-2-thio-5,6-dihydrouracil: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	823208
MeSH ID	M0040319

Synonym
HMS1683N05
1-benzyl-2-sulfanylidene-1,3-diazinan-4-one
nsc50193
19341-60-7
nsc-50193
mls002667345 ,
BAS 00404062
smr001557112
AKOS000505115
4(1h)-pyrimidinone, tetrahydro-1-(phenylmethyl)-2-thioxo-
AKOS005748723
HMS3079G20
nsc 50193
9y8r3kr42q ,
unii-9y8r3kr42q
1-benzyl-2-thio-5,6-dihydrouracil
STL148396
1-benzyl-2-sulfanyl-5,6-dihydropyrimidin-4(1h)-one
DTXSID90172947
SR-01000318742-1
sr-01000318742
tetrahydro-1-(phenylmethyl)-2-thioxo-4(1h)-pyrimidinone
hydrouracil, 1-benzyl-2-thio-
1-benzylhydrouracil
BRD-K60484785-001-05-8

Bioassays (13)

Assay ID	Title	Year	Journal	Article
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1

1-benzyl-2-thio-5,6-dihydrouracil

Description

Cross-References

Synonyms (25)

Bioassays (13)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.35

Study Types

1-benzyl-2-thio-5,6-dihydrouracil

Description

Cross-References

Synonyms (25)

Bioassays (13)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.35

Study Types

Related Conditions (4)